Medicines regulator amends conflict of interest rules to ensure suitability of experts The European Medicines Agency has amended its policy on handling declarations of interest to ensure pharmaceutical experts are not unduly excluded.…
UK government to review access to new medicines and diagnostics Plans may include integrating the health service with life sciences research to bring innovations to patients faster.…
Exploring the history of generic medicines ‘Generic: the unbranding of modern medicine’ by Jeremy A Greene.…
Forces driving the evolution of biologics into biosimilars and biobetters As demand for biologics increases, manufacturers are devising strategies to maximise their returns on investment and benefit patients.…
GlaxoSmithKline and Bayer outperform Roche and Johnson & Johnson in corporate transparency study Many of the world’s 124 largest publicly listed companies disclose little or no financial details about their operations outside their parent country.…
Learn how to apply knowledge management in the pharmaceutical industry ‘Knowledge management in the pharmaceutical industry’ by Elisabeth Goodman and John Riddell.…
Ebola research gets a 280m euro boost from EU and drug industry The European Union has pledged 280m euro to a research project to develop vaccines and diagnostic tests for Ebola.…
Boosting drugs manufacture in developing countries will improve health outcomes, UN investment forum told Increasing pharmaceutical production in developing countries — especially in sub-Saharan Africa — could improve access to affordable medicines, experts say. …
Effective treatments lagging behind for multidrug-resistant TB, says WHO There are still major gaps in delivering effective treatments to patients suffering from multidrug-resistant tuberculosis, a report finds.…
Johnson & Johnson accelerates Ebola vaccine push Johnson & Johnson’s pharmaceuticals unit, Janssen, will invest US$200m in accelerating and expanding production of its Ebola vaccine.…